Premarket trading on Thursday saw a mixed set of market movers across healthcare, semiconductors, airlines and transport, as investors reacted to earnings results, guidance changes and deal news. UnitedHealth shares led gains after the company reported stronger-than-expected quarterly results and lifted its full-year outlook, while Taiwan Semiconductor slipped after raising planned capital spending. In deal-driven action, AtaiBeckley surged following an announced acquisition by Eli Lilly.
Key takeaways
- UnitedHealth shares rose more than 7% as results topped expectations and the company increased its full-year earnings outlook.
- Taiwan Semiconductor shares fell about 4% after the firm increased its full-year capital expenditures guidance and announced an additional Arizona investment.
- AtaiBeckley jumped 34.5% on news Eli Lilly will buy the company for $2.8 billion, implying a premium to the prior close.
- United Airlines shares fell over 3% despite beating earnings expectations, driven by softer third-quarter guidance and higher anticipated fuel costs.
- GE Aerospace dropped roughly 4% even after an earnings and revenue beat, as the stock digested revised expectations.
What drove the move
UnitedHealth: earnings beat and outlook raised
UnitedHealth shares climbed in early trading after the company posted second-quarter results that came in ahead of analysts’ expectations. The health insurer reported adjusted earnings of $6.38 per share on revenue of $112.03 billion. According to analysts polled by LSEG, expectations were for profit of $4.90 per share on revenue of $110.85 billion. The company also increased its full-year earnings outlook, a catalyst that helped offset any valuation sensitivity to near-term margins.
Taiwan Semiconductor: capex reset and growth spending
Taiwan Semiconductor Manufacturing declined about 4% in the premarket session. While the chipmaker’s second-quarter earnings beat estimates, it raised its full-year capital expenditures guidance to a range of between $60 billion and $64 billion, compared with prior guidance of the high end of $52 billion to $56 billion. The company also said it will invest an additional $100 billion in Arizona. Investors often view higher capex as a sign of long-term demand confidence, but the immediate read-through can weigh on sentiment if markets focus on near-term cash flow and execution costs.
AtaiBeckley: acquisition premium lifts the biotech
AtaiBeckley was the standout gainer, jumping 34.5% after Eli Lilly said it will acquire the company for $2.8 billion. The deal implies $6.75 per share in cash, representing a premium over AtaiBeckley’s Wednesday close of $5.36 per share. Lilly could also pay up to an additional $2.50 per share if certain milestone conditions tied to the performance of AtaiBeckley’s drugs are met. Eli Lilly shares were up marginally in premarket trading, suggesting that the market’s focus was on the acquisition’s financing and integration path rather than immediate earnings accretion.
GE Aerospace: beat and higher guidance, but shares slid
GE Aerospace shares fell roughly 4% despite reporting a second-quarter earnings and revenue beat. The company reported adjusted earnings of $2.02 per share on revenue of $12.63 billion, versus LSEG’s expectations for EPS of $1.86 on revenue of $11.86 billion. GE Aerospace also raised its full-year guidance. The downside reaction indicated that investors may have been positioning for a different trajectory in margins, demand, or delivery pace—areas that often matter as much as the headline beat.
United Airlines: earnings beat offset by softer guidance
United Airlines shares dropped more than 3% even though the company topped earnings estimates. The stock reacted to guidance rather than results: the airline issued third-quarter per-share guidance of $2.50 to $3.50, compared with FactSet estimates of $3.53 per share. United also said it expects $6 billion in added fuel costs. For investors, the combination of tighter earnings visibility and higher input costs can outweigh the benefit of a quarterly beat, especially if it implies pressure on profitability later in the year.
J.B. Hunt Transport: intermodal demand cited
J.B. Hunt Transport Services rose nearly 7% after reporting earnings that beat expectations. According to LSEG, the company earned $1.73 per share, 18 cents above analyst estimates. Revenue of $3.5 billion was reported in line with estimates of $3.25 billion. Management highlighted that demand for intermodal services increased throughout the quarter, a detail that likely supported expectations for steadier volume trends.
AeroVironment and Rocket Companies: analyst-driven moves
AeroVironment climbed nearly 2% after a Raymond James upgrade to outperform from market perform. The firm said AeroVironment’s bookings are recovering and its backlog is positioned to grow—two metrics investors typically watch closely for revenue conversion. Rocket Companies added about 2% after Morgan Stanley raised its price target to $19 and reiterated a buy rating. The updated target implied roughly 30% upside from Wednesday’s close, reinforcing a positive analyst stance on the fintech’s outlook.
Market reaction and what investors are watching
The premarket tape suggested investors were selectively rewarding clarity—especially through raised guidance and deal certainty—while penalizing forward visibility when it looks less supportive. UnitedHealth’s rally reflected confidence in earnings power and full-year momentum. United Airlines and GE Aerospace, by contrast, showed that even a beat can fail to satisfy markets when subsequent guidance or cost dynamics point to a more cautious path.
In semiconductors and capital spending-sensitive areas, Taiwan Semiconductor’s update underscored how capex guidance can drive the debate between demand optimism and near-term financial strain. In biotech, AtaiBeckley’s move highlighted that deal premiums can quickly override other concerns, with investors focused on deal terms and milestone outcomes.
Bigger picture
As investors move through the earnings cycle, corporate guidance is proving to be the key differentiator. The market’s reaction across sectors—from insurers and aerospace to airlines and logistics—suggests that investors are prioritizing forward assumptions on costs, spending and growth rather than focusing solely on past-quarter beats. For healthcare and biotech, transaction activity continues to shape expectations for product pipelines and near-term value realization.
Next, traders are likely to concentrate on whether additional companies confirm or revise their outlook, particularly where fuel costs, capital intensity and conversion of backlog into revenue remain central uncertainties. Upcoming earnings releases and major macro updates—including data that can influence interest-rate expectations—may further affect how the market prices risk across these sectors.
